A Dose Range-Finding Study to Assess the Efficacy and Safety of multiple dose levels of AZD8630 in Adults with Uncontrolled Asthma at Risk of Exacerbations - Levante

Study identifier:D6830C00003

ClinicalTrials.gov identifier:NCT06529419

EudraCT identifier:N/A

CTIS identifier:2024-514228-18-00

Recruiting

Official Title

A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Dose Range-Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 Given Once Daily for 12 Weeks in Adults with Uncontrolled Asthma at Risk of Exacerbations (LEVANTE)

Medical condition

asthma

Phase

Phase 2

Healthy volunteers

No

Study drug

AZD8630, Placebo

Sex

All

Estimated Enrollment

516

Study type

Interventional

Age

18 Years - 80 Years

Date

Study Start Date: 30 Aug 2024
Estimated Primary Completion Date: 20 Mar 2026
Estimated Study Completion Date: 07 Apr 2026

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria